Literature DB >> 18179820

Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT).

Yukiyasu Ozawa1, Ann H Williams, Myka L Estes, Norimasa Matsushita, Frank Boschelli, Richard Jove, Alan F List.   

Abstract

We investigated the role of Src family kinases (SFKs) in the regulation of STAT activation in myeloid leukemia cells. Two of 6 AML cell lines displayed constitutive STAT5 activation, whereas four cell lines had constitutive SFK activity. Treatment with the SFK inhibitors suppressed STAT5 activation and decreased viability. Akt phosphorylation and Mcl-1 expression decreased after SFK inhibition accompanied by apoptosis induction. In primary AML specimens, SFK inhibitors suppressed proliferation in 5 of 14 specimens. These data indicate that Src-STAT5 and Src-Akt pathways are integral survival signal pathways in AML cells. Src inhibition may represent a novel treatment strategy for investigation in AML.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18179820     DOI: 10.1016/j.leukres.2007.11.032

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  16 in total

1.  Dietary compounds as potent inhibitors of the signal transducers and activators of transcription (STAT) 3 regulatory network.

Authors:  Anne Trécul; Franck Morceau; Mario Dicato; Marc Diederich
Journal:  Genes Nutr       Date:  2012-01-25       Impact factor: 5.523

Review 2.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer.

Authors:  Daniel E Johnson; Rachel A O'Keefe; Jennifer R Grandis
Journal:  Nat Rev Clin Oncol       Date:  2018-02-06       Impact factor: 66.675

Review 3.  Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Authors:  Mustafa Benekli; Heinz Baumann; Meir Wetzler
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

4.  Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.

Authors:  Bella S Guerrouahen; Muneyoshi Futami; Christos Vaklavas; Jukka Kanerva; Zakary L Whichard; Kenechi Nwawka; Elisabeth G Blanchard; Francis Y Lee; Lisa J Robinson; Robert Arceci; Steven M Kornblau; Eric Wieder; Yvon E Cayre; Seth J Corey
Journal:  Clin Cancer Res       Date:  2010-02-09       Impact factor: 12.531

5.  Aminoisoquinoline benzamides, FLT3 and Src-family kinase inhibitors, potently inhibit proliferation of acute myeloid leukemia cell lines.

Authors:  Elizabeth Larocque; N Naganna; Xiaochu Ma; Clement Opoku-Temeng; Brandon Carter-Cooper; Gaurav Chopra; Rena G Lapidus; Herman O Sintim
Journal:  Future Med Chem       Date:  2017-05-11       Impact factor: 3.808

6.  Stat5 promotes metastatic behavior of human prostate cancer cells in vitro and in vivo.

Authors:  Lei Gu; Paraskevi Vogiatzi; Martin Puhr; Ayush Dagvadorj; Jacqueline Lutz; Amy Ryder; Sankar Addya; Paolo Fortina; Carlton Cooper; Benjamin Leiby; Abhijit Dasgupta; Terry Hyslop; Lukas Bubendorf; Kalle Alanen; Tuomas Mirtti; Marja T Nevalainen
Journal:  Endocr Relat Cancer       Date:  2010-05-18       Impact factor: 5.678

7.  A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.

Authors:  Daniel J Deangelo; Donna Neuberg; Philip C Amrein; Jacob Berchuck; Martha Wadleigh; L Andres Sirulnik; Ilene Galinsky; Todd Golub; Kimberly Stegmaier; Richard M Stone
Journal:  Leuk Res       Date:  2013-11-05       Impact factor: 3.156

8.  FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report.

Authors:  Michele S Redell; Marcos J Ruiz; Robert B Gerbing; Todd A Alonzo; Beverly J Lange; David J Tweardy; Soheil Meshinchi
Journal:  Blood       Date:  2012-12-14       Impact factor: 22.113

9.  Quantification of focal adhesion kinase activation loop phosphorylation as a biomarker of Src activity.

Authors:  Eugene Ciccimaro; Steven K Hanks; Ian A Blair
Journal:  Mol Pharmacol       Date:  2008-12-19       Impact factor: 4.436

10.  The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.

Authors:  Cedric Dos Santos; Tinisha McDonald; Yin Wei Ho; Hongjun Liu; Allen Lin; Stephen J Forman; Ya-Huei Kuo; Ravi Bhatia
Journal:  Blood       Date:  2013-07-29       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.